Trials / Completed
CompletedNCT03790787
Drug Interaction Study Between Dorzagliatin and Empagliflozin
A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Empagliflozin in Subjects with Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Hua Medicine Limited · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration |
| DRUG | Dorzagliatin | Glucokinase activator currently under development |
Timeline
- Start date
- 2019-04-18
- Primary completion
- 2020-03-15
- Completion
- 2020-03-15
- First posted
- 2019-01-02
- Last updated
- 2025-03-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03790787. Inclusion in this directory is not an endorsement.